KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block-Reference-Cited by-同舟云学术

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Published:2022-01 Issue: Volume:16 Page:175346662110660
ISSN:1753-4666
Container-title:Therapeutic Advances in Respiratory Disease
language:en
Short-container-title:Ther Adv Respir Dis

Author:

Garcia-Robledo Juan Esteban¹^ORCID,Rosell Rafael²,Ruíz-Patiño Alejandro³⁴⁴^ORCID,Sotelo Carolina⁴,Arrieta Oscar⁵,Zatarain-Barrón Lucia⁵,Ordoñez Camila⁴,Jaller Elvira⁶,Rojas Leonardo⁷,Russo Alessandro⁸,de Miguel-Pérez Diego⁹,Rolfo Christian⁹,Cardona Andrés F.^ORCID

Affiliation:

1. Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA

2. Cancer Biology and Precision Medicine Program, Germans Trias i Pujol Research Institute (IGTP)/Dr. Rosell Oncology Institute (IOR), Quirón-Dexeus University Institute, Barcelona, Spain

3. Direction of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia

4. Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia

5. Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), México City, México

6. Department of Internal Medicine, Universidad El Bosque, Bogotá, Colombia

7. Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia Department of Clinical Oncology, Clínica Colsanitas, Bogotá, Colombia Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia

8. Medical Oncology Unit, A.O. Papardo, Messina, Italy Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

9. Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

Abstract

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pulmonary and Respiratory Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/17534666211066064

Reference218 articles.

1. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

2. Gender and lung cancer—SEER-based analysis

3. Increasing Lung Cancer Death Rates Among Young Women in Southern and Midwestern States

4. The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers;Cancers;2023-11-25

2. Recent advances in non-small cell lung cancer targeted therapy; an update review;Cancer Cell International;2023-08-11

3. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer;Frontiers in Pharmacology;2023-02-15

4. MET alterations in advanced pulmonary sarcomatoid carcinoma;Frontiers in Oncology;2022-09-23

5. Current treatments for non-small cell lung cancer;Frontiers in Oncology;2022-08-11